- $549.60m
- $477.60m
Brief: Oculis Q2 Net Income CHF -9.97 Million
Swiss stocks - Factors to watch on August 6
NASDAQ RESUMED AT 04:21 PM
Oculis says eye drop misses vision improvement goal in late-stage trials
Brief: Oculis Phase 3 DIAMOND Trials Miss Primary Endpoint For OCS-01 In Diabetic Macular Edema
NASDAQ TRADE HALT HALT NEWS PENDING AT 02:43 PM
Switzerland's Oculis Q1 net loss narrows, cash rises
Swiss stocks - Factors to watch on March 4
Switzerland's Oculis reports wider FY25 net loss
Brief: Oculis Q4 Net Income CHF -23.514 Million
Oculis Q3 net loss CHF 16.9 mln, cash boosted to $300 mln
Brief: Oculis Q3 Net Income CHF -16.855 Million
Swiss stocks - Factors to watch on November 10
Swiss stocks - Factors to watch on June 4
Brief: Oculis Says Prices Offering Of 5 Mln Shares At $20 Each
Oculis climbs on positive mid-stage trial for eye treatment
Brief: Oculis Holding Says Issued Registered Ordinary Shares Of Co, Each With A Nominal Value Of CHF 0.01 For An Aggregate Of 1 Mln Ordinary Shares Of Co
Brief: Oculis Holding AG Entered Into Sales Deal With Leerink Partners Related To At-The-Market Offering Program
Brief: Oculis Announces Completion Of Enrollment In Phase 2 Randomized Controlled Acuity Trial With Ocs-05 For Acute Optic Neuritis